Eribulin in metastatic breast cancer: Real world data.
Breast Dis
; 42(1): 349-360, 2023.
Article
en En
| MEDLINE
| ID: mdl-38073367
ABSTRACT
BACKGROUND:
Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established.OBJECTIVE:
Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature.METHODS:
Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan-Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1.RESULTS:
They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were progression-free-survival (PFS) 3 (IC95% 3-4) versus 3.7 months and overall-survival (OS) 8 (IC95% 3-4) versus 13.2 months for the overall number of patients. For the 1-3 line treatment group, PFS was 6 (IC95% 3-NA) and OS was 15 (IC95% 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38).CONCLUSIONS:
The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Breast Dis
Asunto de la revista:
GINECOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
España